LifeStance Health Group Inc. reached a 52-week high of $12.97 in trading, lifting its market capitalization to approximately $4.81 billion. The stock has surged 129.51% over the past year, outpacing broad market returns.
The provider of outpatient mental-health services posted second-quarter adjusted earnings of $0.06 per share, nearly double the $0.03 consensus estimate compiled by analysts. Revenue came in at $435.35 million, also exceeding the $414.38 million forecast.
Following the results, LifeStance raised its full-year guidance. The company reported 26% revenue growth and a 94% increase in adjusted EBITDA compared with the year-ago period. Adjusted EBITDA for the quarter reached $66 million, pushing the margin to 15.2% from 9.8% a year earlier, according to the company.
Operational metrics reflected continued expansion across its network. Total patient visits totaled 2.6 million, a 19% gain from the prior year, while revenue per visit climbed 6% to $167. Management attributed the results to improvements in productivity, payer contracting, and specialty-service offerings within its outpatient mental-health platform.
Shares were trading around $13 on Friday, giving the stock a PEG ratio of 0.23. The stock has been among the top performers in its sector, building on gains that now sit well above the 52-week low set earlier this year.
The earnings beat and raised outlook followed a quarter in which LifeStance continued to scale its clinic network and expand into higher-margin specialty offerings, reinforcing its position as one of the largest publicly traded mental-health providers in the United States.
